You just read:

BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children

News provided by

BioMarin Pharmaceutical Inc.

21 Apr, 2017, 13:29 ET